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Copyright © 2008 JCBN Summary Properties of mutant δ-aminolevulinate dehydratase (ALAD) found in patients
with ALAD porphyria were studied by enzymological and immunological analyses after the
synthesis of enzyme complexes using a cell-free system. Enzyme activities of homozygous
G133R, K59N/G133R, V153M, and E89K mutants were 11%, 22%, 67%, and 75% of the
wild-type ALAD, respectively, whereas that of K59N, a normal variant, was 112%. Enzyme
activities of L273R, C132R and F12L were undetectable. Co-synthesis of F12L, L273R,
G133R, K59N/G133R, or C132R mutants with the wild-type at various ratios showed that
ALAD activity was proportionally decreased in the amount of the wild-type in the complex.
In contrast, co-synthesis of V153M, K59N, and E89K with the wild-type did not influence
enzyme activity of the wild-type. Surface charge changes in K59N, E89K, C132R and G133R
predicted by mutations were also confirmed by native polyacrylamide gel electrophoresis. A
compound E89K and C132R complex showed ALAD activity similar to that was found in
erythrocytes of the patient. These findings indicate that cell-free synthesis of ALAD proteins
reflects enzymatic activities found in patients, and suggest that, in addition to the direct effect
of mutations on the catalytic activity, conformational effects play an important role in
determining enzyme activity.
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Introduction
Heme is the prosthetic group of all hemoproteins, and
plays a crucial role in fundamentally important physio-
logical reactions [1]. Porphyrias are due to deficiencies of
specific enzymes of the heme biosynthetic pathway. ALAD
(PBG synthase; E.C.4.2.1.24) porphyria (ADP) is an auto-
somal recessive disorder caused by a homozygous ALAD
deficiency. Six unrelated cases of ADP have been reported
to date [2–7]. The molecular defects of the first three
patients were due to six different mutations (R240W and
A274T in German B, G133R and V275M in Swedish boy,
and V153M and L273R in German H) which were inherited
in a compound heterozygous manner, indicating a highly
heterogeneous nature of this disease [4, 8, 9]. The fourth
case was a Belgian adult male who was an exception to the
rule as he developed the disease late in his life due to
heterozygous G133R mutation [10]. G133R had also been
found previously in a Swedish boy with ADP [4]. The fifth
case was the third ADP in Germany, who carried two novel
base changes in intron 3 at –11 bp upstream of the exon 3R. Inoue et al.
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start site [6]. The sixth case carried two novel mutations
within exon 5 of the ALAD gene, resulting in amino acid
substitutions, E89K and C132R, respectively [7]. Both
mutants in this patient influence the binding of the enzyme
to zinc, which is essential for enzyme activity. In addition,
an asymptomatic healthy Swedish girl was found to have a
unique mutant ALAD (F12L) in a heterozygous manner,
with 12% enzyme activity in her erythrocytes [11]. The
F12L mutant, which has also been found in an unrelated
patient [12], has recently been shown that it displays an
altered quaternary structure [13].
ALAD catalyzes an asymmetric condensation of two
molecules of ALA to form PBG [14]. The wild-type ALAD
has been shown to be a homo-octamer composed of four
hugging dimers [15], however, size exclusion studies
suggested that there may also be other quaternary assemblies
in ALAD mutants [16]. For example, though F12L mutation
did not occur at the enzyme’s active site, F12L mutant
protein had a decreased enzyme activity, due to its inability
to form an octameric enzyme [13]. As there is a critical
change in the configuration of an N-terminal arm domain
(residue 1-24) of the wild-type in F12L, it leads to the
formation of a detached dimer, resulting in an inactive
hexamer, instead of an active octamer [13]. Other mutants in
ADP have also been shown to have an increased propensity
to form a low activity hexamer in E. coli expression system
[17]. Based on these findings, Jaffe et al. [ 18] proposed
that low ALAD activity in some ADP may be due to a
disequilibrium of quaternary structure assemblies, and that
ADP may be a conformational disease.
Although homozygous or compound heterozygous
deficiency of ALAD is very rare, heterozygous enzyme
deficiency with 50% normal enzyme activity may not be so
rare, as the prevalence of such condition was reported to be
2% in a normal healthy population [3]. These individuals
with low ALAD activity are clinically unaffected, but may
potentially be more vulnerable than normal subjects to toxic
effects of chemicals or compounds which inhibit ALAD
activity [19]. Thus it may be important, from an environ-
mental and prophylactic point of view, to detect heterozy-
gous carriers of ALAD deficiency and to define the nature of
their enzymatic defect. In fact, ALAD in the heterozygous
carriers of an ADP mutation, namely parents of an ADP
patient, showed a decreased sensitivity to lead [7].
In order to study the nature of decreased ALAD activities
of various ADP mutants, we expressed a mixture of the
wild-type and mutant ALAD mRNAs in this study using a
cell-free protein synthesizing system to produce an enzyme
complex as it occurs in patients’ cells. Cell-free system was
prepared from insect cells, with pTD1 plasmid as an expres-
sion vector, which included the translational enhancer
sequence derived from Malacosma neustria nucleopoly-
hedrovirus polyhedrin gene [20]. Various ratios of mRNA
mixture transcribed from pTD1 plasmid, which encoded the
wild-type human ALAD or ALAD mutant cDNAs, were
used. Characterization of the synthesized proteins was
performed by colorimetric enzyme assays of ALAD activity,
and by immunoblot analysis of the proteins separated by
PAGE with SDS, followed by detection with a polyclonal
antibody against human ALAD. Oligomeric features of the
synthesized protein complex were examined using PAGE
without SDS (native-PAGE).
Materials and Methods
Construction of expression plasmid
The cDNAs encoding the wild-type and mutant ALAD
(F12L, K59N, G133R, K59N/G133R, V153M, L273R,
E89K, C132R), which have been found in patients with
ADP [7, 9–11], were cloned into pGEM-T Easy vector, and
used as the template for the second PCR. Primers used were
as follows: a sense primer corresponding to 5'-untranslated
region of ALAD cDNA containing the initiation codon; 5'-
GGGATATCATGCAGCCCCAGT-3', which was designed
to have Eco RV site at the 5' end, and an antisense primer
corresponding to 3'-untranslated region; 5'-GTTCTAGAG-
GGCCTGGCACTGTCCTCCA-3', which was designed to
have Eco RI site at the 5' end. PCR products were purified by
phenol-chloroform extraction, and were inserted into
pGEM-T Easy vector (Promega, Madison, WI). Nucleotide
sequencing was performed by the dideoxy chain-termination
method (SequiTherm Long-Read Cycle Sequencing Kits
LC., Epicetre-Technologies, Madison, WI) [21]. Subcloned
ALAD cDNAs were digested with Eco RV and Eco RI,
followed by purification with QIAEX II Gel Extraction Kit
(Qiagen,Tokyo, Japan), and then cDNA fragments were
ligated into the pTD1 vector (Shimazu, Kyoto, Japan),
which was also digested with Eco RV and Eco RI.
Synthesis of the wild-type and mutant ALADs in cell-free
protein synthesis system
Plasmid pTD1, which encoded ALAD cDNAs, were
digested with Hind III, and used as the template for mRNA
production using CUGA 7 in vitro Transcription Kit
(NIPPON GENETECH, Tokyo, Japan), as described in the
manufacture’s protocol. Messenger RNAs were collected
and purified by ethanol precipitation and used for the protein
synthesis. ALAD proteins were synthesized by addition of
prepared mRNA(s) with Transdirect insect cell (Shimazu
co.), according to the manufacture’s protocol.
Immunoblot analysis of proteins synthesized by cell-free
system
Human ALAD was specifically detected by immunoblot
analysis using rabbit IgG versus human ALAD [22].
Synthesized proteins were heated at 100°C for 3 min in SDSHeterozygous Oligomerization of Human ALAD
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gel-loading buffer (50 mM Tris-Cl (pH 6.8), 100 mM DTT,
2% SDS, 0.1% bromophenol blue, and 10% glycerol). The
samples were loaded on to a 10% polyacrylamide gel
containing 0.01% SDS, and electrophoresed according to the
method described previously (SDS-PAGE) [23]. In order to
assess the quaternary structure of synthesized protein, PAGE
under a non-denaturing condition (native-PAGE) was
carried out, by loading untreated proteins onto the gel
without SDS and electrophoresed in the absence of SDS
[11]. Samples were then transferred to a sheet of nitro-
cellulose membrane and incubated overnight at 4°C with
10% skim milk in Tris-buffered saline. The membrane
was incubated with the primary antibody for 1 h at room
temperature. Goat anti-rabbit IgG, conjugated with horse-
radish peroxidase was used as a secondary antibody. Protein
bands to which antibodies were bound were visualized with
the enhanced chemiluminescence (ECL) immunoblotting
system (Amersham Life Science, Buckinghamshire, England),
which was performed according to manufacturer’s protocol.
ALAD activity assay
ALAD activity of synthesized proteins was determined
colorimetrically as described previously [14]. ALAD
activity was expressed as the percent of that of the wild-type
ALAD, and the specific activity was calculated as ALAD
activity per ALAD protein estimated by SDS-PAGE.
Results
Cell-free synthesis of ALAD enzyme complex
In order to determine the effect of ALAD mutations on
enzyme activity and composition of multimeric enzyme
complexes, the wild-type or mutant ALAD mRNA was
translated in a cell-free protein synthesis system. The wild-
type and mutant ALADs were detected as a single band at
the predicted size of Mr. 36 kDa by SDS-PAGE followed by
immunoblot analysis, with the exception of L273R
(Fig. 1A). L273R mutant was a deletion mutant, with 2 base
deletions at 818 and 819, resulting in a frame shift with a
premature stop codon at amino acid residue 294 [9]. The
predicted size of L273R monomer is 32 kDa, which was also
confirmed by SDS-PAGE. In contrast to SDS-PAGE, ALAD
proteins applied to native-PAGE resulted in various patterns,
reflecting differences in the surface charge of various
oligomers (Fig. 1B). The wild-type and V153M mutant
ALADs were detected as three bands, with an identical
mobility pattern for both isoforms. The three bands
presumably reflected an octamer, a hexamer and a dimer in
the enzyme complex, as judged from their migration. F12L
mutant showed two bands, which corresponded to the
hexamer and the dimer of the wild-type complex, as reported
previously [13]. K59N/G133R mutant, which was found in
an adult Belgian ADP patient [10], showed a similar pattern
as F12L, suggesting that this mutant may also assemble as a
low activity hexamer. K59N has one less positive charge
per unit than the wild-type enzyme, and, as expected, the
mobility of its three bands was slightly faster than those of
the wild-type. In contrast to K59N, G133R and C132R have
one more positive charge per unit than the wild-type, and
both mutants resulted in a drastic change in the proportion of
the octamer to the dimer. E89K, which has two more
positive charges per unit than the wild-type, resulted in a
similar pattern as the wild-type but with a significantly
slower mobility. L273R, the only deletion mutant identified
in ADP, did not show any detectable band in native-PAGE.
ALAD activities of the synthesized proteins (Fig. 1C) were
all correlated with the amount of the octamer formed in the
enzyme complex (Fig. 1B).
Co-synthesis of F12L with the wild-type ALAD
To reproduce the ALAD protein found in a healthy subject
with a 12% ALAD activity due to heterozygous F12L
mutation, ALAD mixture was synthesized in cell-free
protein synthesis system by using mRNAs of the wild-type
and F12L at different ratios (Fig. 2). These enzyme com-
plexes analyzed in native-PAGE showed two bands, one
corresponding to the octamer reflecting principally the
wild-type, and the other corresponding to the hexamer
reflecting F12L, consistent with the findings reported pre-
viously in E. coli expression system [13]. An increase in
F12L in the mixture led to a decrease in the octamer forma-
tion, and decreased enzyme activity. ALAD protein
synthesized from a mixture of an equal amount of the wild-
type and F12L mRNAs was predominantly represented by
the low active hexamer, with significant reduction in the
amount of the active octamer. In addition, the amount of the
fastest moving isoform, i.e., the dimer, increased signifi-
cantly when both ALAD forms were synthesized at an equal
ratio of their mRNA. These findings may also account for a
12%, rather than an expected 50%, ALAD activity found in
erythrocytes of the subject who was heterozygous for F12L
mutation [11].
Effect of ALAD mutants on the wild-type ALAD conforma-
tion
L273R and V153M, found in a German ADP patient [9],
were co-synthesized with the wild-type ALAD by cell-free
system (Fig. 3). Proteins synthesized showed a mixture of
two different sizes by SDS-PAGE, one corresponding to the
wild-type (36 kDa), while the other corresponding to L273R
(32 kDa) (Fig. 3A). Native-PAGE results showed not only a
decreased amount of the octamer but also that of a hexamer
and a dimer, when the wild-type-mutant ratio was decreased.
Moreover, the amount of octamer detected by native-PAGE
was correlated with that of the wild-type ALAD detected
by SDS-PAGE (Fig. 3A, B), suggesting that L273R mutantR. Inoue et al.
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formed no oligomer. ALAD activities found in these pro-
teins were well correlated with the amount of the octamer
(Fig. 3B, C, D). Although the other ALAD mutant, V153M,
produced as an immunologically positive low activity pro-
tein in CHO cells [9], V153M mutant itself had significant
enzyme activity, accompanied by heteromeric octamer for-
mation as judged from native-PAGE analysis. The enzyme
activities found in the complex were also correlated with the
amount of the octamer in the complex (Fig. 3B, C).
G133R was found both in a Swedish child [4], and in a
Belgian adult with ADP [10]. Using CHO cells transfected
with G133R cDNA, it was demonstrated that this mutation
was indeed responsible for the enzyme defect, which is due
to a decreased binding of the enzyme to zinc. G133R
synthesized in vitro in this study showed a serial decrease in
the amount of the octamer as well as its enzyme activity, in
proportion to a serial increase in the amount of the mutant
mRNA in cell-free system (Fig. 4B, C, D). Hetero-
oligomers of K59N, a normal variant previously also
reported as ALAD2 [24–26] with the wild-type were
examined using the same cell-free system (Fig. 4). ALAD
activity was not affected at all by changing the ratio of the
mutant in the mixture to the wild-type (Fig. 4C). Since the
surface charge of K59N was altered, hetero-oligomers
composed of the wild-type and K59N were expected to
show different mobility in native-PAGE. Proteins synthe-
sized in vitro by the wild-type and K59N mRNAs showed
indeed sequential differences in mobility of oligomers in
native-PAGE in parallel to an increase in K59N in the
enzyme complex (Fig. 4B), suggesting that K59 and N59
were freely composed to form a hetero-dimer and a hetero-
octamer, without affecting enzyme activity (Fig. 4C). Since
the Belgian patient carried G133R and K59N on the same
allele, we examined the nature of K59N/G133R complex
synthesized by cell-free system (Fig. 4). Since K59N resulted
in the loss of a positive charge but G133R gained a positive
charge, the mobility of this mutant-wild-type complex in
native-PAGE was expected to be similar to that of the wild-
type, and the results also confirmed this view (Fig. 4). The
property of hetero-oligomers composed of the wild-type and
K59N/G133R was quite similar to that of the wild-type and
G133R hetero-oligomers (Fig. 4).
The first ADP patient in North America carried two novel
point mutations, i.e. E89K and C132R, both affecting
Fig. 1. ALAD mutants synthesized in cell-free system. ALAD protein synthesis followed by the immunoblot analysis and enzyme
assay was carried out as described in “Materials and methods.” (A) Immunoblot analysis after SDS-PAGE. The molecular size
of the wild-type and mutants were 36 kDa, except for L273R, which was 32 kDa. (B) Immunoblot analysis after native-PAGE.
(C) ALAD activities in synthesized proteins. Data are the mean ± SE of triplicate assays.Heterozygous Oligomerization of Human ALAD
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enzyme’s sensitivity to lead [7]. Since the surface charge of
E89K has been altered from negative to positive by the
mutation, mobility in native-PAGE was expected to be
significantly different. In fact, both the octamer (the main
form) and the hexamer (the minor form) moved slower than
those in the wild-type, when the amount of E89K was
increased in the complex (Fig. 5B). It should be noted that
the dimer was detected as three different bands, and each
band presumably represented a homozygous wild-type, a
heterozygous wild-type/E89K, and a homozygous E89K
(Fig. 5B). Enzyme activity decreased only slightly with an
increase in the amount of the mutant in the complex
(Fig. 5C). In contrast, C132R in the complex decreased
ALAD activity more significantly than did E89K (Fig. 5C).
Results of native-PAGE suggested that C132R may also
form three forms of the dimer, as did E89K (Fig. 5B). ALAD
activity of these complexes was well correlated with the
amount of the hetero-octamer of the wild-type and C132R in
the complex (Fig. 5D).
Compound heterozygous expression of E89K and C132R by
cell-free synthesis to mimic the condition in the patient
Finally compound heterozygous expression of E89K and
C132R was examined that would have mimicked the
condition in the patient [7]. These molecular defects were
extensively studied by enzymological, immunological as
well as by molecular analysis in blood samples from the
proband and his family members (Table 1). Since C132R
mutant is more stable than E89K by approximately two-fold
[7], mRNAs encoding E89K and C132R were mixed at a
ratio of 1 to 2. Results of three independent experiments all
showed that the amount of the active octamer decreased to
22 ± 2% (mean ± SE) of the wild-type (Fig. 6B). Enzyme
activity of the complex was also 20% ± 1% (mean ± SE) of
the wild-type. Since the level of ALAD protein in the patient
was about 44% of the normal subjects [7] (Table 1), ALAD
activity brought about by E89K-C132R hetero-octamer in
the patient was estimated to be about 9% of the wild-type,
which was roughly similar to that actually observed in the
Fig. 2. Co-synthesis of F12L with the wild-type isoform. Messenger RNA encoding F12L ALAD variant is mixed with that of the
wild-type in various ratios. ALAD protein synthesis followed by the immunoblot analysis and enzyme assay was carried out as
described in “Materials and Methods.” (A) Immunoblot analysis after SDS-PAGE. (B) Immunoblot analysis after native-PAGE.
(C) ALAD activities in synthesized proteins. Data are the mean ± SE of triplicate assays.R. Inoue et al.
J. Clin. Biochem. Nutr.
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patient’s erythrocytes (1% of normal) (Table 1).
Discussion
Eleven different molecular defects of ALAD have been
reported to date in patients with ADP. In this study, we
examined the properties of seven mutants as well as those of
the wild-type and K59N, a normal variant, by synthesizing
them either as a homo- or a hetero-oligomer, using cell-free
system. The wild-type ALAD is known to occur as a homo-
octamer, consisting of four hugging dimers, and the homo-
octameric configuration is thought to be essential for its
enzyme activity [13]. The enzyme activity is also critically
dependent on the availability of zinc, the essential cofactor.
For example, displacement of zinc by lead inhibits enzyme
activity, while supplementation of zinc relieves the enzyme
from the lead-mediated inhibition [27]. ALAD mutations
such as C132R, G133R and E89K have been shown to occur
at or in the vicinity of the active site, i.e., the zinc binding
site of the enzyme, and are thought to account for the
observed loss of enzyme activity in cells in these patients
[4, 7, 10]. In contrast, F12L mutation which resulted in a
major decrease in enzyme activity in a healthy subject
heterozygous for this mutation does not involve the active
site, suggesting that other aspects may also be important in
affecting enzyme activity. Further analysis of F12L mutation
demonstrated that there is a critical change in the configura-
tion of an N-terminal arm domain (residue 1-24) of the
wild-type in F12L, resulting in the formation of a detached
dimer and a low active hexamer, rather than a hugging
dimmer and a high active octamer. This finding indicated
that conformational alteration may significantly influence
enzyme activity. When mutants in ADP such as E89K,
C132R, G133R, R240W and A274T were studied by E. coli
Fig. 3. Co-synthesis of L273R or V153M with the wild-type isoform. Messenger RNA encoding L273R ALAD variant is mixed with
that of the wild-type in various ratios (left side). The same experiment was carried out using V153M instead of L273R (right
side). ALAD protein synthesis followed by the immunoblot analysis and enzyme assay was carried out as described in
“Materials and Methods.” (A) Immunoblot analysis after SDS-PAGE. (B) Immunoblot analysis after native-PAGE. (C) ALAD
activities in synthesized proteins. Data are the mean ± SE of triplicate assays. (D) The relationship between the enzyme activity
and octamer, which was calculated as % of the wild-type. Data are the mean ± SE of triplicate assays.Heterozygous Oligomerization of Human ALAD
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expression system, evidence also suggested that these
mutants have an increased propensity to form a low activity
hexamer. Based on these findings, Jaffe et al. [18] suggested
that ADP may be a conformational disease.
In order to clarify the question whether an alteration in the
enzyme assembly may influence its activity, we synthesized
ALAD mutants found in ADP by using an insect-cell based
cell-free system, together with the wild-type and a normal
variant K59N, and studied their properties by enzymological
and immunological analyses. Our studies demonstrated that
ALAD proteins were produced as respective homo- and
hetero-oligomeric complexes, and ALAD activities of
enzyme complexes were well correlated with the amount of
octamers.
There have been a few other studies that examined ALAD
activity of the ADP mutants by using different expression
systems. These results are summarized in Table 2, together
with our findings in this study. The results of our present
study based on cell-free synthesis were generally in good
agreement with those reported from other systems such as
stable expression in CHO cells, E.coli expression system
and fused with glutathione S-transferase (GST) and expressed
in E.coli [7, 9–11, 18, 28]. Mutant ALADs synthesized by
our cell-free system had, however, generally higher enzyme
activity than those obtained by other expression systems
(Table 2). The reasons for the observed difference remain
unclear, but the products by our cell-free system must be
more stable than those obtained by cell-based expression
systems, since proteins synthesized by our system are
completely free from endogenous proteolysis.
It has been shown that the wild-type ALAD assembles as
a homo-octamer and is thought to be responsible for a high
enzyme activity found in normal tissues such as circulating
erythrocytes [29], while F12L mutant which fails to form
an octamer results in insignificant enzyme activity [13].
Decreased amounts of octamers were found in C132R,
G133R and K59/G133R, which were also accompanied by
low enzyme activity (Fig. 1). As expected, mutants having
different surface charges, e.g., K59N, E89K, C132R and
G133R, showed different mobilities in native-PAGE.
Fig. 4. Co-synthesis of G133R, K59N or K59/G133R with the wild-type isoform. Messenger RNA encoding G133R ALAD variant is
mixed with that of the wild-type in various ratios (left side). The same experiment was carried out using K59N (middle) or K59/
G133R (right side), instead of G133R. ALAD protein synthesis followed by the immunoblot analysis and enzyme assay was
carried out as described in “Materials and Methods.” (A) Immunoblot analysis after SDS-PAGE. (B) Immunoblot analysis after
native-PAGE. (C) ALAD activities in synthesized proteins. Data are the mean ± SE of triplicate assays. (D) The relationship
between the enzyme activity and octamer, which was calculated as % of the wild-type. Data are the mean ± SE of triplicate
assays.R. Inoue et al.
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Fig. 5. Co-synthesis of E89K or C132R with the wild-type isoform. Messenger RNA encoding E89K ALAD variant is mixed with that
of the wild-type in various ratios (left side). The same experiment was carried out using C132R instead of E89K (right side).
ALAD protein synthesis followed by the immunoblot analysis and enzyme assay was carried out as described in “Materials and
Methods.” (A) Immunoblot analysis after SDS-PAGE. (B) Immunoblot analysis after native-PAGE. (C) ALAD activity in
synthesized proteins. ALAD activity was measured as described in “Materials and Methods.” Data are the mean ± SE of
triplicate assays. (D) The relationship between the enzyme activity and octamer, which was calculated as % of the wild-type.
Data are the mean ± SE of triplicate assays.
Table 1. ALAD activity and protein levels determined in the blood from individuals carrying ALAD defect(s)
ND; not determined
ALAD mutant Activity (% of normal) Protein (% of normal) Reference
Homozygous
V153M L273R 1.3 11 [9, 30]
E89K C132R 1 44 [7]
Heterozygous
F12L 12–39 91 [11, 12]
L273R 34 44 [9, 30]
V153M 53 ND [9, 30]
G133R 23–33 22–59 [3]
K59N/G133R 28–32 ND [5]
E89K 50 67–78 [7]
C132R 45 63 [7]Heterozygous Oligomerization of Human ALAD
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Enzyme activities of these mutants also well reflected the
amount of octamers in the enzyme complex (Fig. 1). Our
results thus suggest that, in addition to the lack of enzyme
activity due to a mutation directly affecting the active site,
the disruption of quaternary structure assemblies leading to
a decreased formation of the octamer is another important
factor for a decreased enzyme activity observed in certain
patients with ADP.
Co-expression of the wild-type ALAD and F12L in E. coli
resulted in a hetero-oligomer consisting of each isoform
[13]. Our present study showed that a mixture of an equal
amount of the wild-type and F12L mRNA in a cell-free
system yielded a dimer, a hexamer and an octamer (Fig. 2B).
These results confirm the proposal made by an earlier study
that the high active octamer and low active hexamer as well
as dimer, may assemble as hetero-oligomers [13, 17].
A wild-type and a mutant ALAD hetero-oligomers are
expected to exist in cells of family members of ADP
patients, with a decrease of ALAD activity in a half-normal
range (Table 1). In this study, when a wild-type and a mutant
such as L273R, G133R, K59N/G133R, C132R, were co-
synthesized, enzyme complexes showed a decreased amount
of octamers in the complex, as well as decreased ALAD
activity which was proportional to the decreased amount of
the octamer (Fig. 3, 4, 5). K59N synthesized by cell-free
system showed a similar ALAD activity as the wild-type, a
finding similar that reported by studies using CHO cells and
E, coli (Table 2). It was also evident that K59N formed an
octameric assembly with normal enzyme activity (Fig. 4).
The mobility of proteins of their complexes composed of
various ratios of the wild-type and a mutant also resulted in
a shift of proteins in proportion to a decrease in the surface
charge. Similar results were also observed with G133R,
E89K or C132R when they were co-synthesized with the
wild-type (Fig. 4, 5).
Hetero-dimers as well as homo-dimers formed by the
wild-type and E89K, or C132R, were clearly detected by
native-PAGE (Fig. 5). As these dimers were derived from
the active enzyme complex which moved more slowly than
the wild-type when the amount of the mutant was increased
in the complex, these findings suggest that the dimeric
complexes must have constituted a part of the active
octamer. These results also suggest that ALAD hetero-
dimers may dissociate from the complex, may change con-
formation, and/or may re-assemble into a different hetero-
oligomer with different function. Compound heterozygosity
of E89K and C132R in the patient in vivo and C132R
octamer in vitro showed little enzyme activity, while E89K
octamer showed a significant enzyme activity in vitro,
suggesting that C132R exerts a dominant negative effect
over E89K (Fig. 6).
The results in the present study establish the fact that, in
addition to the effect of mutations directly involving the
active site, a disequilibrium in quaternary structure assem-
Table 2. ALAD activities (% of WT) of mutants found in the patients with ADP by using various expression system
ND; not determined
Expression system F12L G133R K59N
K59N/
G133R
V153M L273R E89K C132R
CHO cells ≠0 8.1 94.6 16 11 ≠01 0 4
E. coli 0.2 12 100 ND 38 ND 64 0.3
E. coli (GST-fusion protein) 1 8 70 8 41 1 ND ND
cell-free system 7 11 112 22 67 3 75 4
Fig. 6. Compound heterozygous synthesis of ALAD mutants.
Mixture of mRNAs encoding E89K and C132R ALAD
at the ratio of 1 to 2 and was used for the template of
protein synthesis. ALAD protein synthesis followed by
the immunoblot analysis and enzyme assay was carried
out as described in “Materials and Methods.” (A)
Immunoblot analysis after SDS-PAGE. (B) Immunoblot
analysis after native-PAGE. (C) ALAD activities in syn-
thesized proteins. Data are the mean ± SE of triplicate
assays.R. Inoue et al.
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blies of ALAD also plays a critical role in determining
enzyme activity. Use of various ratios of different ALAD
mRNAs in cell-free system also demonstrated that signifi-
cant enzymatic activity is closely correlated with the amount
of an active octamer in the enzyme complex. Thus cell-free
synthesis of polymeric ALAD enzyme complex is indeed a
very useful approach for the investigation into the conforma-
tional influences of mutations on enzyme activity, and our
study based on such method provided molecular explanation
of decreased enzymatic activity in patients with ADP in
vivo.
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